Latest Insider Transactions at Turning Point Therapeutics, Inc. (TPTX)
This section provides a real-time view of insider transactions for Turning Point Therapeutics, Inc. (TPTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Turning Point Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Turning Point Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 17
2022
|
Paolo Tombesi EVP & Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
29,778
-100.0%
|
$2,263,128
$76.0 P/Share
|
|
Aug 17
2022
|
Brian Sun SVP & General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
45,000
-100.0%
|
$3,420,000
$76.0 P/Share
|
|
Aug 17
2022
|
Steve M Sabus SVP & Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
36,667
-100.0%
|
$2,786,692
$76.0 P/Share
|
|
Aug 17
2022
|
Mohammad Hirmand EVP and Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
41,284
-100.0%
|
$3,137,584
$76.0 P/Share
|
|
Aug 17
2022
|
Simeon George Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,253,660
-100.0%
|
$171,278,160
$76.0 P/Share
|
|
Aug 17
2022
|
Athena Countouriotis President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
110,959
-100.0%
|
$8,432,884
$76.0 P/Share
|
|
Aug 17
2022
|
Mark J Alles Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,000
-100.0%
|
$152,000
$76.0 P/Share
|
|
Jul 27
2022
|
Paolo Tombesi EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,183
-3.96%
|
$87,542
$74.94 P/Share
|
|
May 31
2022
|
Steve M Sabus SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,667
+50.0%
|
-
|
|
Apr 11
2022
|
Brian Sun SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+50.0%
|
-
|
|
Feb 09
2022
|
Athena Countouriotis President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
62,400
+36.13%
|
-
|
|
Feb 09
2022
|
Athena Countouriotis President & CEO |
SELL
Open market or private sale
|
Direct |
2,971
-5.84%
|
$106,956
$36.3 P/Share
|
|
Feb 09
2022
|
Mohammad Hirmand EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,983
+34.62%
|
-
|
|
Feb 09
2022
|
Mohammad Hirmand EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
669
-8.91%
|
$24,084
$36.3 P/Share
|
|
Feb 09
2022
|
Annette North EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
16,283
+36.79%
|
-
|
|
Feb 09
2022
|
Annette North EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
669
-5.41%
|
$24,084
$36.3 P/Share
|
|
Feb 09
2022
|
Andrew John Partridge EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,283
+29.8%
|
-
|
|
Feb 09
2022
|
Andrew John Partridge EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
221
-0.99%
|
$7,956
$36.3 P/Share
|
|
Feb 09
2022
|
Siegfried Reich EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,567
+44.36%
|
-
|
|
Feb 09
2022
|
Siegfried Reich EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
397
-10.33%
|
$14,292
$36.3 P/Share
|
|
Feb 09
2022
|
Paolo Tombesi EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,283
+35.27%
|
-
|
|
Aug 30
2021
|
Annette North EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
10,000
-44.71%
|
$800,000
$80.0 P/Share
|
|
Aug 30
2021
|
Annette North EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+30.9%
|
$170,000
$17.0 P/Share
|
|
Jul 26
2021
|
Paolo Tombesi EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,600
+50.0%
|
-
|
|
Jul 14
2021
|
Andrew John Partridge EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,869
-7.91%
|
$138,306
$74.9 P/Share
|
|
Jun 21
2021
|
Mark J Alles Director |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$162,000
$81.34 P/Share
|
|
Jun 15
2021
|
Annette North EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
15,000
-22.69%
|
$1,155,000
$77.04 P/Share
|
|
Jun 15
2021
|
Annette North EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+35.41%
|
$255,000
$17.0 P/Share
|
|
May 06
2021
|
Annette North EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,882
+32.24%
|
$99,994
$17.0 P/Share
|
|
Mar 23
2021
|
Brian Lee Baker SVP of Finance and Admin. |
SELL
Open market or private sale
|
Direct |
28,435
-23.39%
|
$2,843,500
$100.99 P/Share
|
|
Mar 23
2021
|
Brian Lee Baker SVP of Finance and Admin. |
BUY
Exercise of conversion of derivative security
|
Direct |
28,435
+22.88%
|
$113,740
$4.49 P/Share
|
|
Mar 22
2021
|
Brian Lee Baker SVP of Finance and Admin. |
BUY
Grant, award, or other acquisition
|
Direct |
1,625
+28.31%
|
-
|
|
Mar 08
2021
|
Annette North EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
20,000
-22.7%
|
$2,160,000
$108.95 P/Share
|
|
Mar 08
2021
|
Annette North EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+43.03%
|
$340,000
$17.0 P/Share
|
|
Mar 04
2021
|
Siegfried Reich EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
35,550
-19.9%
|
$3,768,300
$106.52 P/Share
|
|
Mar 04
2021
|
Siegfried Reich EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,550
+47.43%
|
$1,813,050
$51.28 P/Share
|
|
Feb 11
2021
|
Athena Countouriotis President & CEO |
SELL
Open market or private sale
|
Direct |
8,942
-5.3%
|
$1,225,054
$137.55 P/Share
|
|
Feb 11
2021
|
Athena Countouriotis President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,942
+13.13%
|
$26,826
$3.2 P/Share
|
|
Feb 10
2021
|
Athena Countouriotis President & CEO |
SELL
Open market or private sale
|
Direct |
25,392
-7.43%
|
$3,453,312
$136.43 P/Share
|
|
Feb 10
2021
|
Athena Countouriotis President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,392
+25.15%
|
$76,176
$3.2 P/Share
|
|
Feb 09
2021
|
Athena Countouriotis President & CEO |
SELL
Open market or private sale
|
Direct |
25,666
-7.64%
|
$3,541,908
$138.49 P/Share
|
|
Feb 09
2021
|
Athena Countouriotis President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,666
+15.03%
|
$76,998
$3.2 P/Share
|
|
Feb 08
2021
|
Athena Countouriotis President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
22,617
+31.06%
|
-
|
|
Feb 08
2021
|
Brian Lee Baker SVP of Finance and Admin. |
BUY
Grant, award, or other acquisition
|
Direct |
1,483
+37.32%
|
-
|
|
Feb 08
2021
|
Siegfried Reich EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,845
+50.0%
|
-
|
|
Feb 08
2021
|
Yi Larson EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,617
+38.67%
|
-
|
|
Feb 08
2021
|
Andrew John Partridge EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,136
+8.29%
|
-
|
|
Feb 08
2021
|
Annette North EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
6,483
+50.0%
|
-
|
|
Feb 08
2021
|
Mohammad Hirmand EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,483
+48.93%
|
-
|
|
Feb 02
2021
|
Yi Larson EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,298
-26.34%
|
$1,844,442
$129.62 P/Share
|